| First Author | Lai Y | Year | 2013 |
| Journal | Proc Natl Acad Sci U S A | Volume | 110 |
| Issue | 2 | Pages | 525-30 |
| PubMed ID | 23185009 | Mgi Jnum | J:192576 |
| Mgi Id | MGI:5465392 | Doi | 10.1073/pnas.1211431109 |
| Citation | Lai Y, et al. (2013) alpha2 and alpha3 helices of dystrophin R16 and R17 frame a microdomain in the alpha1 helix of dystrophin R17 for neuronal NOS binding. Proc Natl Acad Sci U S A 110(2):525-30 |
| abstractText | Homologous spectrin-like repeats can mediate specific protein interaction. The underlying mechanism is poorly understood. Dystrophin contains 24 spectrin-like repeats. However, only repeats 16 and 17 (R16/17) are required for anchoring neuronal NOS (nNOS) to the sarcolemma. Through an adeno-associated virus-based in vivo binding assay, we found that membrane expression of correctly phased R16/17 was sufficient to recruit nNOS to the sarcolemma in mouse muscle. Utrophin R15/16 is homologous to dystrophin R16/17. Substitution of dystrophin R16/17 microdomains with the corresponding regions of utrophin R15/16 suggests that the nNOS binding site is located in a 10-residue fragment in dystrophin R17 alpha1 helix. Interestingly, swapping this microdomain back into utrophin did not convey the nNOS binding activity. To identify other structural features that are required for nNOS interaction, we replaced an individual alpha-helix of dystrophin R16/17 with an equivalent alpha-helix from another dystrophin repeat. In vitro study with yeast two-hybrid suggests that most alpha-helices of R16/17, except for the R17 alpha1 helix, were dispensable for nNOS interaction. Surprisingly, in vivo binding assay showed that alpha2 and alpha3 helices of both R16 and R17 were essential for nNOS binding in muscle. We concluded that a microdomain in the alpha1 helix of dystrophin R17 binds to nNOS in a way uniquely defined by two pairs of the flanking helices. Our results provide an explanation for how structurally similar spectrin-like repeats in dystrophin display selective interaction with nNOS. The results also open new therapeutic avenues to restore defective nNOS homeostasis in dystrophin-null Duchenne muscular dystrophy. |
